Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| PSP Pharma | Pharma | 6.8% | 30th pct | 110 |
| Impexpharm | Pharma | 6.3% | 26th pct | 110 |
| SmartPharm | Pharma | 5.4% | 23rd pct | 110 |
| Pharmaceutical House+ | Pharma | — | no FY data | 110 |
| Iberi + | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Ratio — FY 2024 | PSP Pharma | Impexpharm | SmartPharm | Pharmaceutical House+ | Iberi + |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 22.5% | 29.9% | 16.4% | — | — |
| EBITDA Margin | 6.8% | 6.3% | 5.4% | — | — |
| EBITDAR | 57,112 | 6,960 | 2,278 | — | — |
| EBITDAR Margin | 6.8% | 6.3% | 6.2% | — | — |
| EBIT Margin | 4.4% | 1.7% | 5.1% | — | — |
| Net Profit Margin | 3.4% | 2.6% | 5.2% | — | — |
| Operating Expense % of Sales | 15.7% | 23.5% | 11.0% | — | — |
| Returns | |||||
| Return on Assets (ROA) | 4.3% | 3.1% | 11.5% | — | — |
| Return on Equity (ROE) | 8.9% | 4.8% | 14.5% | — | — |
| ROIC [EBIT / Invested Capital] | 8.9% | 2.5% | 15.8% | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 16.9% | 19.5% | 0.0% | — | — |
| Debt-to-Equity | 0.35x | 0.30x | 0.00x | — | — |
| Debt-to-EBITDA | 1.97x | 2.62x | 0.00x | — | — |
| Equity-to-Assets | 48.6% | 64.5% | 79.0% | — | — |
| Net Debt | 91,853 | 14,819 | -1,279 | — | — |
| Cash & Equivalents | 20,687 | 3,447 | 1,279 | — | — |
| Total Debt | 112,540 | 18,266 | N/A | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.58x | 3.36x | 4.27x | — | — |
| Quick Ratio | 0.41x | 0.93x | 0.89x | — | — |
| Cash Ratio | 0.08x | 0.23x | 0.37x | — | — |
| Total Current Assets | 392,371 | 50,341 | 14,872 | — | — |
| Total Current Liabilities | 248,714 | 14,987 | 3,483 | — | — |
| Inventory | 291,297 | 36,452 | 11,772 | — | — |
| Trade Receivables | 76,883 | 4,885 | 1,782 | — | — |
| Trade Payables | 192,919 | 14,756 | 3,483 | — | — |
| Net Working Capital | 143,657 | 35,354 | 11,389 | — | — |
| Net Working Capital % of Revenue | 17.0% | 32.1% | 31.1% | — | — |
| Trade Working Capital | 175,261 | 26,582 | 10,071 | — | — |
| Trade Working Capital % of Revenue | 20.7% | 24.1% | 27.5% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.25x | 2.12x | 2.60x | — | — |
| Days Inventory Outstanding (DIO) | 162.3 | 172.2 | 140.4 | — | — |
| Receivables Turnover | 10.99x | 22.55x | 20.55x | — | — |
| Days Sales Outstanding (DSO) | 33.2 | 16.2 | 17.8 | — | — |
| Payables Turnover | 3.40x | 5.24x | 8.79x | — | — |
| Days Payable Outstanding (DPO) | 107.5 | 69.7 | 41.5 | — | — |
| Cash Conversion Cycle | 88.0 days | 118.6 days | 116.6 days | — | — |
| Asset Turnover | 1.27x | 1.18x | 2.21x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 20,831 | 12,244 | 926 | — | — |
| Free Cash Flow (OCF − Capex proxy) | 19,867 | 8,715 | 248 | — | — |
| Cash Conversion (OCF / EBITDA) | 36.5% | 175.9% | 46.6% | — | — |
| Dividends Declared | 31,235 | 2,737 | 375 | — | — |
| Dividend Payout Ratio | 107.8% | 94.6% | 19.7% | — | — |